Creating sustainability and longevity for biosimilars

At AmerisourceBergen, we believe in the promise of biosimilars to deliver cost savings across healthcare. We also understand the potential hurdles these unique products will face. That's why we offer solutions for increasing access to and confidence in these emerging therapies.

Distribution & Commercialization Services

For manufacturers

Our experts can help you devise channel strategies and tailored solutions for access and uptake. And, we have market-leading reach into the sites of care where patients are being treated with biosimilars.

Education & Reimbursement Support

for providers

Our market-leading GPOs connect physicians and manufacturers for unrivaled purchasing power and education. Plus, field reimbursement support helps practices navigate payment for these new products.

Providers and consultant

Impacting Access, Affordability & Adherence

for patients

Our patient assistance program (PAP) models and adherence services are tailored to your product and patient needs and integrate seamlessly with our reimbursement and co-pay services.

Connect With an Expert

Sean McGowan, Sr. Director, Biosimilars at amerisourcebergen

Spotlight on Biosimilars

Biosimilar Pipeline Report

A guide for understanding the growing market

This reference guide is a useful tool to visualize and understand the current product landscape and potential future of this emerging market, in which AmerisourceBergen has access to 100% of launched biosimilars in the U.S..

State of Biosimilars

a presentation on the biosimilars market

Discover the current state and challenges of biosimilars and learn from external experts on the projections of this promising product category.

Watch the presentation

The Changing Biosimilar Landscape

In partnership with fierce pharma

COVID-19 changed the way physician practices and health systems interacted with patients, but Sean McGowan, senior director of biosimilars at AmerisourceBergen, said customers have found their footing in this new operating environment. It has been a successful year and 2021 looks just as promising.

Watch the video

graphs with stethoscope

New Podcast Episode - Biosimilars: Patents, policy, and reimbursement

In the inaugural episode of the AmerisourceBergen Insights podcast, we’re looking at the biosimilars market with Sean McGowan, Senior Director of Biosimilars at AmerisourceBergen. Sean will be joined by David Senior and Steve Miller to discuss the policy and reimbursement issues that impact our customers and the overall growth of biosimilars.

Biosimilars Check Up: Part 2

While biosimilar manufacturers may seemingly face the same commercialization challenges as any manufacturer (coverage, competition, and patient access), physician confidence is critical, creating an additional layer of challenges – and launch considerations.

Download the results

Biosimilar Markets to Keep an Eye On

Sean McGowan, Senior Director of Biosimilars at AmerisouceBergen, discusses the current biosimilar pipeline and the potential impact on the market those products may have. Hosted by The Center for Biosimilars.

We advance access with integrated commercialization services for all biosimilars

Field Reimbursement Support

Powered by Xcenda

GPO Access & Provider Education

Powered by ION Solutions

HUB & Patient Services

Powered by Lash Group

Market Access Consulting

Powered by Xcenda

“The recent pandemic state produced a spotlight on the need to drive savings within the U. S. pharmaceutical market – biosimilars are one of many solutions to reducing downstream cost. The importance of staying diligent and continuing to drive choice, access and savings is a top priority at AmerisourceBergen.”

-Michelle Jesse, Director, Biosimilar Commercialization

Our relationships span:

health systems

100%

of u.s. hospitals

oncology

60%

of U.S. community oncology market

nephrology

90%

of U.S. renal market

opHthamology

4,200

provider sites

rheumatology

2,100

provider sites

Resources & Education

Read the FDA's guidance on biosimilars and get answers to patients' frequently asked questions.

Visit site

"The right conditions exist in the U.S. for biosimilar commercialization success. Competition has proven to bring prices down – look at the generics market over the last 30 years – but now we need to create a supportive system."

STEVE COLLIS, CHAIRMAN, PRESIDENT AND CEO, AMERISOURCEBERGEN

Read more